Maxeon Solar Technologies Stock (NASDAQ: MAXN)

Dernières nouvelles pour Maxeon Solar Technologies (NASDAQ:MAXN) Stock

Maxeon Solar Technologies

Maxeon Solar Technologies Ltd is engaged in the manufacturing and marketing of premium solar technology. It owns and operates solar cell and panel manufacturing facilities located in Malaysia, Mexico, and the Philippines. The company's primary products are the Maxeon line of interdigitated back contact (IBC) solar cells and panels, and the Performance line (formerly, P-Series) of shingled solar cells and panels. the Maxeon line of solar panels are the highest-efficiency solar panels on the market with an aesthetically pleasing design, and the Performance line of solar panels offers a high-value and cost-effective solution. It is targeted at residential and small-scale commercial customers across the globe. The company derives its revenue from the United States, France, Italy, and others.

Maxeon Solar Technologies, Ltd. - Ordinary Shares

Maxeon Solar Technologies Ltd

B of A Securities analyst Ken Hoexter maintains World Kinect (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WKC#NYSE">WKC</a>) with a Underperform and lowers the price target from $27 to $26.

News

Price Target

Analyst Ratings

B of A Securities Maintains Underperform on World Kinect, Lowers Price Target to $26

Needham analyst Mike Matson maintains Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Buy and lowers the price target from $116 to $100.

MMSI

Needham Maintains Buy on Merit Medical Systems, Lowers Price Target to $100

Key financial highlights:
<ul>
<li>The Company also closed on an amended $400 million revolving credit facility with U.S. Bank National Association, JP Morgan Chase Bank, N.A., Wells Fargo Bank, N.A., and Associated Bank, N.A., increasing the size from $250 million and with rates similar to our previous credit facility.</li>
<li>Hawkins intends to use the cash on hand and available borrowings to fund the acquisition.</li>
<li>Hawkins proforma leverage ratio will be approximately 1.7x trailing 12-month proforma adjusted EBITDA, leaving significant availability for future tuck-in acquisitions.</li>
<li>WaterSurplus generated adjusted EBITDA of approximately $10 million for the fiscal year ending December 31, 2024.</li>
<li>The acquisition is expected to be accretive to Hawkins' earnings per share in fiscal year 2027, and improves the margin profile of Hawkins' current Water Treatment business.</li>
</ul>

HWKN

Hawkins Completes Acquisition Of Assets Of Surplus Management, Doing Business As WaterSurplus

WIIM

MGRX

Mangoceuticals shares are trading higher after the company entered an Intellectual Property Purchase Agreement for IP and assets of Smokeless Technology Corp.

Mangoceuticals Enters Intellectual Property Purchase Agreement To Acquire Intellectual Property, Product Formulations, Know-How, Distribution, Supplier Relationships And Related Assets Of Smokeless Technology Corp.; Terms Not Disclosed

<ul>
<li>In ASPEN-03 and ASPEN-04 trials, efficacy data do not support advancing evorpacept in combination with Merck's anti-PD-1 therapy, KEYTRUDA&#xAE; (pembrolizumab), into a registrational study</li>
<li>Company remains confident in continuing to pursue evorpacept in multiple clinical trials, based on the different mechanism of evorpacept in combination with anti-cancer antibodies, as evidenced by durable clinical response and consistent safety data in prior clinical trials ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXO#NASDAQ">ALXO</a>), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced topline data from its Phase 2 ASPEN-03 and ASPEN-04 clinical trials. The company's investigational CD47-blocker evorpacept, when added to Merck's (known as MSD outside of the US and Canada) anti-PD-1 therapy, KEYTRUDA&#xAE; (pembrolizumab) with or without chemotherapy, did not meet the primary endpoints in the ASPEN-03 and ASPEN-04 trials of improved objective response rates (ORR) as compared to historical controls of pembrolizumab alone and pembrolizumab with chemotherapy, respectively, as a first-line treatment in patients with advanced head and neck squamous cell carcinoma (HNSCC). The combination of evorpacept and pembrolizumab with or without chemotherapy in ASPEN-03 and ASPEN-04 demonstrated a manageable safety profile and was consistent with what has been previously reported for pembrolizumab and chemotherapy in this setting. Although the company will no longer pursue evorpacept in combination with pembrolizumab in HNSCC, multiple clinical trials of evorpacept in combination with anti-cancer antibodies will continue based on established proof-of-concept.</li>
</ul>
Evorpacept blocks the ‘don't eat me' signal transmitted by CD47 on the surface of cancer cells that these cells use to evade detection by the immune system. As its primary mechanism of action, evorpacept is uniquely designed to stimulate macrophages to selectively attack cancer cells and not healthy cells, when combined with active anti-cancer antibodies. This mechanism has translated into durable clinical responses and a well-tolerated safety profile in HER2-positive gastric and HER2-positive breast cancer clinical trials. To further explore the benefit in this setting, evorpacept is currently being evaluated in combination with various anti-cancer antibodies in colorectal cancer, breast cancer, non-Hodgkin lymphoma and multiple myeloma.
In the ASPEN-03 and ASPEN-04 clinical trials, evorpacept was combined with pembrolizumab with or without chemotherapy to investigate a second and distinct mechanism of action. This discrete approach explored the concept that evorpacept may enhance T-cell priming by activating dendritic cells and stimulating the adaptive immune system. The trial outcomes were not sufficiently supportive of advancing evorpacept in combination with pembrolizumab in HNSCC into a registrational trial.
"While there were encouraging trends in ASPEN-03 in ORR versus the historical and internal control, we've decided not to pursue evorpacept and pembrolizumab in head and neck cancer in light of our prioritization of the more established anti-cancer antibody combination program based on multiple positive studies," said Alan Sandler, M.D., Chief Medical Officer at ALX Oncology. "We are disappointed that these studies did not meet their primary endpoints, most importantly for the patients for whom current standard-of-care treatment approaches fall short, and we thank all who participated in the trials."
"Moving forward, we are continuing to rapidly advance our clinical program combining evorpacept with anti-cancer antibodies supported by robust clinical data across trials in multiple tumor types. Evorpacept has demonstrated response rates and durability beyond what is expected from standard of care across several studies when combined with HERCEPTIN&#xAE;, zanidatamab and RITUXAN&#xAE;," said Jason Lettmann, Chief Executive Officer at ALX Oncology. "Based on the positive data and strong mechanistic rationale, we maintain our confidence in the evorpacept clinical development program and intend to deliver on that promise with additional clinical data in breast cancer and colorectal cancer in the near-term. With evorpacept and ALX2004, our novel EGFR-targeted antibody-drug conjugate, we continue our commitment to bringing forth meaningful therapies for patients living with cancer."

Biotech

General

ALXO

ALX Oncology Announces ASPEN-03 And ASPEN-04 Phase 2 Trials Evaluating Evorpacept With A Checkpoint Inhibitor For The Treatment Of Head And Neck Cancers Did Not Meet Primary Endpoints

- Label includes full spectrum of PKU patients -
- European launch preparations underway -
WARREN, N.J., April 25, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion on the marketing authorization application for Sephience&#x2122; (sepiapterin) for the treatment of children and adults living with phenylketonuria (PKU). The opinion includes a broad label inclusive of all ages and disease severities.

PTCT

PTC Therapeutics: CHMP Of EMA Issues Positive Opinion On Marketing Authorization Application For Sephience For Treatment Of Children And Adults Living With Phenylketonuria

B of A Securities analyst Craig Bijou maintains PROCEPT BioRobotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCT#NASDAQ">PRCT</a>) with a Buy and lowers the price target from $104 to $84.

PRCT

B of A Securities Maintains Buy on PROCEPT BioRobotics, Lowers Price Target to $84

VSTM

Verastem shares are trading higher after the company announced a private placement.

Verastem Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors for a private placement of approximately $24 million of shares of its common stock at a price of $7.00 per share and, in lieu of common stock to certain investors, $51 million of pre-funded warrants to purchase shares of its common stock at a price of $6.9999 per pre-funded warrant. The exercise price of each pre-funded warrant will equal $0.0001 per share. Verastem expects to receive gross proceeds from the offering of approximately $75 million, before deducting placement agent fees and other offering expenses.

Verastem Oncology Announces $75M Private Placement

HCA Healthcare Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) reported on Friday that first-quarter 2025 revenues were $18.32 billion, up 6% year-over-year, slightly above the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $18.26 billion</a>.
The hospital chain reported adjusted EPS of $6.45, up from $5.36 a year ago, surpassing the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b45005010/hca-healthcare-reports-first-quarter-2025-results" rel="noreferrer noopener">consensus of $5.76</a>.
In the first quarter of 2025, same-facility admissions increased by 2.6%, and same-facility equivalent admissions increased by 2.8%.
<ul>
<li>Same facility emergency room visits increased by 4%.</li>
<li>Same-facility inpatient surgeries increased by 0.2%, and same-facility outpatient surgeries declined by 2.1%.</li>
<li>Same facility revenue per equivalent admission increased 2.9% compared to the first quarter of 2024.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44995364/zoom-faces-international-growth-risks-amid-macroeconomic-and-tariff-headwinds-analyst" rel="noreferrer noopener">Zoom Faces International Growth Risks Amid Macroeconomic And Tariff Headwinds: Analyst</a>
HCA Healthcare CEO Sam Hazen said the company remains &#8220;encouraged&#8221; by the overall backdrop of growing demand for healthcare services.
Net income attributable to HCA Healthcare totaled $1.61 billion compared to $1.591 billion a year ago.
Adjusted EBITDA reached $3.73 billion in the first quarter of 2025, compared to $3.353 billion in the first quarter of 2024.
Guidance:&nbsp;HCA Healthcare reaffirms 2025 EPS of $24.05-$25.85 versus a consensus of $24.97 and a <a target="_blank" href="https://www.benzinga.com/general/health-care/25/01/43192622/hca-healthcare-q4-earnings-beat-steet-estimates-despite-hurricane-impact-announces-10-billion-share-buyback-program" rel="noreferrer noopener">sales outlook of $72.8 billion—$75.8 billion</a> versus a consensus of $74.63 billion.
The company&#8217;s guidance incorporated its current expectations regarding volume growth coupled with an anticipated mostly stable operating environment, payer mix, the ongoing impacts of the two major 2024 hurricanes, the impact of current and future health care public policy developments, as well as general business or economic conditions, including inflation, and the impact of trade policies, including tariffs.
Price Action:&nbsp;HCA Healthcare stock is down 0.463% at $323.86&nbsp;at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44996394/chipotle-battles-slumping-sales-but-honey-chicken-boosts-hope-say-analysts" target="_blank" rel="noreferrer noopener">Chipotle Battles Slumping Sales, Analyst Pin Hope On Honey Chicken</a></li>
</ul>

Earnings

Large Cap

Guidance

Health Care

HCA Healthcare Shows Strong Pulse In Q1, Keeps 2025 Outlook Healthy

Verint Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNT#NASDAQ">VRNT</a>) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $28.4, a high estimate of $30.00, and a low estimate of $23.00. This current average has decreased by 20.22% from the previous average price target of $35.60. 
<img src="https://www.benzinga.com/files/images/story/2025/1745586059_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Verint Systems by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Joshua Reilly &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $30.00&#x7C;$30.00 &#x7C; 
&#x7C;Daniel Ives &#x7C;Wedbush &#x7C;Lowers &#x7C;Outperform &#x7C; $30.00&#x7C;$38.00 &#x7C; 
&#x7C;Dan Bergstrom &#x7C;RBC Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $29.00&#x7C;$36.00 &#x7C; 
&#x7C;Peter Levine &#x7C;Evercore ISI Group &#x7C;Lowers &#x7C;In-Line &#x7C; $23.00&#x7C;$34.00 &#x7C; 
&#x7C;Joshua Reilly &#x7C;Needham &#x7C;Lowers &#x7C;Buy &#x7C; $30.00&#x7C;$40.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Verint Systems. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Verint Systems compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Verint Systems's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Verint Systems's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/VRNT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Verint Systems analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Verint Systems</h2>
Verint Systems Inc with its subsidiaries, helps brands provide Boundless customer experience (CX) automation. AI offers a solution, and that's where Verint comes in. It empowers brands with groundbreaking AI via a next-gen open platform. Its Verint Open Platform helps organizations increase CX automation to achieve their strategic objectives and realize ROI. Geographically, it derives a majority of its revenue from the United States.
<h3>Verint Systems's Financial Performance</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Verint Systems's revenue growth over a period of 3M has faced challenges. As of 31 January, 2025, the company experienced a revenue decline of approximately -4.36%. This indicates a decrease in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Verint Systems's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 11.35% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Verint Systems's ROE stands out, surpassing industry averages. With an impressive ROE of 3.26%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Verint Systems's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.27% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Verint Systems's debt-to-equity ratio is below the industry average at 0.51, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VRNT

Expert Outlook: Verint Systems Through The Eyes Of 5 Analysts

In the preceding three months, 12 analysts have released ratings for The Hartford Insurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIG#NYSE">HIG</a>), presenting a wide array of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">9</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for The Hartford Insurance Gr, revealing an average target of $132.5, a high estimate of $145.00, and a low estimate of $117.00. This upward trend is apparent, with the current average reflecting a 1.92% increase from the previous average price target of $130.00.
<img src="https://www.benzinga.com/files/images/story/2025/1745586050_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive The Hartford Insurance Gr. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;-----------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Alex Scott &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $145.00&#x7C;$140.00 &#x7C; 
&#x7C;Alex Scott &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $140.00&#x7C;$135.00 &#x7C; 
&#x7C;Yaron Kinar &#x7C;Jefferies &#x7C;Lowers &#x7C;Hold &#x7C; $117.00&#x7C;$118.00 &#x7C; 
&#x7C;Elyse Greenspan &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $125.00&#x7C;$126.00 &#x7C; 
&#x7C;Meyer Shields &#x7C;Keefe, Bruyette &amp; Woods&#x7C;Lowers &#x7C;Outperform &#x7C; $133.00&#x7C;$140.00 &#x7C; 
&#x7C;Jimmy Bhullar &#x7C;JP Morgan &#x7C;Raises &#x7C;Neutral &#x7C; $129.00&#x7C;$125.00 &#x7C; 
&#x7C;Paul Newsome &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $145.00&#x7C;$130.00 &#x7C; 
&#x7C;C. Gregory Peters &#x7C;Raymond James &#x7C;Raises &#x7C;Outperform &#x7C; $135.00&#x7C;$125.00 &#x7C; 
&#x7C;Meyer Shields &#x7C;Keefe, Bruyette &amp; Woods&#x7C;Raises &#x7C;Outperform &#x7C; $140.00&#x7C;$139.00 &#x7C; 
&#x7C;Scott Heleniak &#x7C;RBC Capital &#x7C;Maintains &#x7C;Sector Perform &#x7C; $125.00&#x7C;$125.00 &#x7C; 
&#x7C;Paul Newsome &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $130.00&#x7C;$127.00 &#x7C; 
&#x7C;Elyse Greenspan &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $126.00&#x7C;$130.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to The Hartford Insurance Gr. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of The Hartford Insurance Gr compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of The Hartford Insurance Gr's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of The Hartford Insurance Gr's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/HIG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on The Hartford Insurance Gr analyst ratings.</a>
<h2>About The Hartford Insurance Gr</h2>
The Hartford Insurance Group Inc. provides property and casualty insurance, group benefits, and mutual funds. The company is widely recognized for its service excellence, sustainability practices, trust, and integrity. The Company currently conducts business principally in five reportable segments including Business Insurance, Personal Insurance, Property &amp; Casualty Other Operations, Employee Benefits, and Hartford Funds, as well as a Corporate category. The company generates a majority of its revenue from Business Insurance.
<h3>Key Indicators: The Hartford Insurance Gr's Financial Health</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: The Hartford Insurance Gr's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 7.54%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 12.47%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 5.17%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The Hartford Insurance Gr's ROA stands out, surpassing industry averages. With an impressive ROA of 1.05%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.27, The Hartford Insurance Gr adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying The Hartford Insurance Gr: Insights From 12 Analyst Reviews

During the last three months, 12 analysts shared their evaluations of Cognizant Tech Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSH#NASDAQ">CTSH</a>), revealing diverse outlooks from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Cognizant Tech Solns, revealing an average target of $87.25, a high estimate of $103.00, and a low estimate of $77.00. Observing a downward trend, the current average is 0.19% lower than the prior average price target of $87.42. 
<img src="https://www.benzinga.com/files/images/story/2025/1745586040_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Cognizant Tech Solns among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Ramsey El-Assal &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $90.00&#x7C;$103.00 &#x7C; 
&#x7C;James Friedman &#x7C;Susquehanna &#x7C;Lowers &#x7C;Neutral &#x7C; $77.00&#x7C;$82.00 &#x7C; 
&#x7C;David Koning &#x7C;Baird &#x7C;Lowers &#x7C;Neutral &#x7C; $78.00&#x7C;$90.00 &#x7C; 
&#x7C;Daniel Perlin &#x7C;RBC Capital &#x7C;Maintains &#x7C;Sector Perform &#x7C; $93.00&#x7C;$93.00 &#x7C; 
&#x7C;Kevin Mcveigh &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $88.00&#x7C;$93.00 &#x7C; 
&#x7C;James Faucette &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $80.00&#x7C;$85.00 &#x7C; 
&#x7C;Ramsey El-Assal &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $103.00&#x7C;$95.00 &#x7C; 
&#x7C;Daniel Perlin &#x7C;RBC Capital &#x7C;Raises &#x7C;Sector Perform &#x7C; $93.00&#x7C;$82.00 &#x7C; 
&#x7C;James Faucette &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Equal-Weight &#x7C; $85.00&#x7C;$80.00 &#x7C; 
&#x7C;Keith Bachman &#x7C;BMO Capital &#x7C;Raises &#x7C;Market Perform &#x7C; $94.00&#x7C;$88.00 &#x7C; 
&#x7C;Kevin Mcveigh &#x7C;UBS &#x7C;Raises &#x7C;Neutral &#x7C; $86.00&#x7C;$83.00 &#x7C; 
&#x7C;James Faucette &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Equal-Weight &#x7C; $80.00&#x7C;$75.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Cognizant Tech Solns. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Cognizant Tech Solns compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Cognizant Tech Solns's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Cognizant Tech Solns's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CTSH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Cognizant Tech Solns analyst ratings.</a>
<h2>Get to Know Cognizant Tech Solns Better</h2>
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 350,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
<h3>A Deep Dive into Cognizant Tech Solns's Financials</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Cognizant Tech Solns's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 6.81%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Cognizant Tech Solns's net margin excels beyond industry benchmarks, reaching 10.74%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Cognizant Tech Solns's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 3.78%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Cognizant Tech Solns's ROA stands out, surpassing industry averages. With an impressive ROA of 2.72%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Cognizant Tech Solns's debt-to-equity ratio is below the industry average at 0.1, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CTSH

What Analysts Are Saying About Cognizant Tech Solns Stock

In the latest quarter, 4 analysts provided ratings for Stoneridge (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRI#NYSE">SRI</a>), showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $16.0, a high estimate of $16.00, and a low estimate of $16.00. Consistency is reflected as the current average remains at the same level as the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2025/1745586033_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The perception of Stoneridge by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Gary Prestopino &#x7C;Barrington Research &#x7C;Maintains &#x7C;Outperform &#x7C; $16.00&#x7C;$16.00 &#x7C; 
&#x7C;Gary Prestopino &#x7C;Barrington Research &#x7C;Maintains &#x7C;Outperform &#x7C; $16.00&#x7C;$16.00 &#x7C; 
&#x7C;Gary Prestopino &#x7C;Barrington Research &#x7C;Maintains &#x7C;Outperform &#x7C; $16.00&#x7C;$16.00 &#x7C; 
&#x7C;Gary Prestopino &#x7C;Barrington Research &#x7C;Maintains &#x7C;Outperform &#x7C; $16.00&#x7C;$16.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Stoneridge. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Stoneridge compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Stoneridge's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SRI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Stoneridge analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Stoneridge</h2>
Stoneridge Inc is a manufacturer of electrical and electronic components used in automotive vehicles. The company produces instrumentation systems, vehicle management electronics, application-specific switches and actuators, sensors, security alarms, and vehicle tracking devices and monitoring services for commercial, automotive, off-highway, and agricultural vehicle markets. The company has three reportable segments: Control Devices, Electronics, and Stoneridge Brazil. It generates the majority of its revenue from the Electronics segment that produces driver information systems, camera-based vision systems, connectivity, and compliance products, and electronic control units. Its geographic segments include America, South America, Europe and Other.
<h3>Stoneridge: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Challenges: Stoneridge's revenue growth over 3M faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -4.91%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.
Net Margin: Stoneridge's net margin is impressive, surpassing industry averages. With a net margin of -2.8%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Stoneridge's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -2.37%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Stoneridge's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.95% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Stoneridge's debt-to-equity ratio surpasses industry norms, standing at 0.85. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Stoneridge: 4 Analysts Share Their Views

SEI Investments's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEIC#NYSE">SEIC</a>) short percent of float has risen 30.13% since its last report. The company recently reported that it has 3.26 million shares sold short, which is 2.98% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.52 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>SEI Investments Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745586032_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for SEI Investments has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing SEI Investments's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, SEI Investments's peer group average for short interest as a percentage of float is 3.56%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

SEIC

Looking Into SEI Investments's Recent Short Interest

As of April 25, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Lexicon Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>)</h3>
<ul>
<li>On March 28, Lexicon Pharmaceuticals entered into an exclusive license agreement with Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) for LX9851, a first-in-class, oral non-incretin development candidate in obesity and associated metabolic disorders. Under the terms of the agreement, Novo Nordisk obtains an exclusive, worldwide license to develop, manufacture, and commercialize LX9851 in all indications. The company's stock jumped around 95% over the past month and has a 52-week high of $2.45.</li>
<li>RSI Value: 73.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>LXRX Price Action: Shares of Lexicon Pharmaceuticals gained 4.7% to close at $0.70 on Thursday.</li>
<li>Edge Stock Ratings: 5.71 Momentum score with Value at 55.06. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/lxrx"><img loading="lazy" decoding="async" width="472" height="182" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25045347/image-168.png" alt="" class="wp-image-888292" style="width:303px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25045347/image-168.png 472w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25045347/image-168-300x116.png 300w" sizes="(max-width: 472px) 100vw, 472px" /></a></figure>
<h3 class="wp-block-heading">Amarin Corporation PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>)</h3>
<ul>
<li>On March 12, Amarin announced its intent to effect a 1-for-20 ADS ratio change. The company also reported fourth-quarter financial results. &#8220;Since taking on the role of CEO of Amarin last year, I have worked with our leadership team and the Board of Directors to identify opportunities to leverage our unique assets, skills and resources to drive value,&#8221; said Aaron Berg, President &amp; CEO, Amarin. &#8220;In 2024, while still progressing with the early launch in markets outside the U.S. and despite a dynamic generic market in the U.S., we generated more than $200 million in revenue and ended the year with nearly $300 million in cash and no debt &#8212; all measures exemplifying the strength and resilience of our franchise and the impact of our disciplined approach to capital deployment.&#8221; The company's stock gained around 24% over the past five days and<a href="https://www.benzinga.com/quote/AMRN"> has a 52-week high</a> of $20.60.</li>
<li>RSI Value: 73.5</li>
<li>AMRN Price Action: Shares of Amarin rose 7.9% to close at $11.18 on Thursday.</li>
</ul>
BZ Edge Rankings: Find out where other stocks stand—<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">explore the full comparison now</a>. 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44977071/wall-streets-most-accurate-analysts-weigh-in-on-3-materials-stocks-with-over-7-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Materials Stocks With Over 7% Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

AMRN

LXRX

Top 2 Health Care Stocks That May Crash This Month

Silgan Hldgs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLGN#NYSE">SLGN</a>) short percent of float has fallen 34.71% since its last report. The company recently reported that it has 2.20 million shares sold short, which is 2.37% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.11 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Silgan Hldgs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745586026_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Silgan Hldgs has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Silgan Hldgs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Silgan Hldgs's peer group average for short interest as a percentage of float is 4.95%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

SLGN

How Do Investors Really Feel About Silgan Hldgs?

Nu Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $14.6, along with a high estimate of $16.00 and a low estimate of $13.00. A decline of 4.58% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1745586024_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The perception of Nu Holdings by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;John Coffey &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $16.00&#x7C;$15.00 &#x7C; 
&#x7C;Domingos Falavina &#x7C;JP Morgan &#x7C;Lowers &#x7C;Overweight &#x7C; $13.00&#x7C;$14.00 &#x7C; 
&#x7C;John Coffey &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $15.00&#x7C;$17.00 &#x7C; 
&#x7C;Domingos Falavina &#x7C;JP Morgan &#x7C;Lowers &#x7C;Neutral &#x7C; $14.00&#x7C;$15.00 &#x7C; 
&#x7C;Thiago Batista &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $15.00&#x7C;$15.50 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Nu Holdings. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Nu Holdings compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Nu Holdings's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Nu Holdings's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NU/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Nu Holdings analyst ratings.</a>
<h2>Unveiling the Story Behind Nu Holdings</h2>
Nu Holdings Ltd provides digital banking services. It offers several financial services such as Credit cards, Personal accounts, Investments, Personal Loans, Insurance, Mobile payments, Business Accounts, and Rewards. The company earns the majority of its revenue in Brazil.
<h3>Nu Holdings's Financial Performance</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Nu Holdings displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 24.68%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 26.19%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Nu Holdings's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 7.23%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Nu Holdings's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.12%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.08.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Nu Holdings In The Eyes Of 5 Experts

Carlyle Secured Lending's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CGBD#NYSE">CGBD</a>) short percent of float has fallen 23.53% since its last report. The company recently reported that it has 376 thousand shares sold short, which is 0.52% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.42 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Carlyle Secured Lending Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745586022_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Carlyle Secured Lending has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Carlyle Secured Lending's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Carlyle Secured Lending's peer group average for short interest as a percentage of float is 2.71%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

CGBD

What Does the Market Think About Carlyle Secured Lending?

Commodities

Stock Split

Press Releases

Maxeon Receives Nasdaq Notification and is Proceeding with Approved Reverse Stock Split

Pomerantz Law Firm Announces the Filing of a Class Action Against Maxeon Solar Technologies, Ltd. - MAXN

Maxeon Announces CEO Leadership Transition

Maxeon Provides Update on CBP Detention of its Solar Panels

Maxeon Announces Restructuring of Business Portfolio

Maxeon Solar Technologies Announces Third Quarter 2024 Financial Results

Maxeon and Tongwei Solar Announce Settlement Agreement Resolving Patent Infringement Lawsuit

Maxeon Provides Strategic Business Update

MAXN

Ascent Solar Technologies, Inc - Common Stock

Ascent Solar Technologies

Datavault AI

GCT Semiconductor Holding, Inc. Common Stock

GCT Semiconductor Hldgs

GSI Technology

Intchains Group Limited - American Depositary Shares

Intchains Gr

Kopin

SemiLEDs

Mobix Labs

Everspin Technologies, Inc. - Common Stock

Everspin Technologies

Magnachip Semiconductor Corporation Common Stock

MagnaChip Semiconductor

Nano Labs

Peraso

Pixelworks

QuickLogic

Semilux International Ltd. - Ordinary Shares

Semilux International

SmartKem

Sequans Communications S.A. American Depositary Shares (each representing ten (10) Ordinary Shares)

Comments

Maxeon Solar Technologies

Actualités

Dernières nouvelles pour Maxeon Solar Technologies (NASDAQ:MAXN) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL